Common polymorphisms in the glyoxalase-1 gene and their association with pro-thrombotic factors

Abstract

Advanced glycation endproducts (AGEs) form at an accelerated rate in diabetes and contribute to the development of macrovascular disease. Their precursors are detoxified by the glyoxalase system. Perturbations of the glyoxalase-1 gene may alter AGEs' interactions and affect pro-thrombotic factors.

We screened the glyoxalase-1 gene for mutations and measured pro-thrombotic markers in 537 subjects from 89 healthy probands. Common single nucleotide polymorphisms (SNPs) were identified at positions-7 (C to T) and 20203 (C to A) from the translation start site. These SNPs were in Hardy-Weinberg equilibrium (CC=105, CA=266, AA=148; p>0.05; CC=126, CT=279, TT=114; p>0.05, respectively) and in linkage disequilibrium (D=27%, p<0.01), with mutant allele frequencies of 48% and 52% respectively.

A significant association was found between SNPs at position 20203 and PAI-1 antigen concentrations and-7 and factor XIII A2B2 complex (p=0.001 and p=0.042). After Bonferroni correction a significant association remained between the SNP at 20203 and PAI-1 concentrations (p=0.005), and after adjustment for pedigree the association accounted for 1.3% of its heritability (p=0.04). No significant associations were found for SNP-7 T to C and factor VII activity, tPa concentrations, fibrinogen concentrations or factor XIII concentrations and SNP 20203 C to A and factor VII concentrations, PAI-1 concentrations, tPa concentrations or fibrinogen concentrations.

Common variants in the glyoxalase-1 gene are associated with some pro-thrombotic factors, account for part of their heritability in healthy pedigrees and may alter susceptibility to macrovascular complications.

Keywords

glyoxalase-1 advanced glycation endproducts plasminogen activator inhibitor-1 factor XIII

References

1. Kannel WB , McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979;2:120–6.

2. Pyorala K. Diabetes and coronary artery disease: what a coincidence?. J Cardiovasc Pharmacol 1990;16(suppl 9):S8–S1S4.

3. Stamler J , Vaccaro O , Neaton JD , Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434–44.

4. Brownlee M , Cerami A. The biochemistry of the complications of diabetes mellitus. Annu Rev Biochem 1981;50:385–432.

5. Kruithof EK , Tran-Thang C , Ransijn A , Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984;64:907–13.

6. Dawson S , Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis 1992;95:105–17.

7. Paramo JA , Colucci M , Collen D , van de Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. BMJ (Clin Res Ed) 1985;291:573–4.

8. Hamsten A , de Faire U , Walldius G et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3–9.

9. Small M , Kluft C , MacCuish AC , Lowe GD. Tissue plasminogen activator inhibition in diabetes mellitus. Diabetes Care 1989;12:655–8.

10.

10. Auwerx J , Bouillon R , Collen D , Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988;8:68–72.

11.

11. Kohler HP , Grant PJ. The role of factor XIIIVal34Leu in cardiovascular disease. Q J Med 1999;92:67–72.

12.

12. Vlassara H. Chronic diabetic complications and tissue glycosylation. Relevant concern for diabetes-prone black population. Diabetes Care 1990;13:1180–5.

13.

13. Schmidt AM , Hori O , Brett J , Yan SD , Wautier JL , Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arteriosclerosis Thrombosis 1994;14:1521–8.

14.

14. Brownlee M , Cerami A , Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1998;318:1315–21.

15.

15. Yamagishi S , Fujimori H , Yonekura H , Yamamoto Y , Yamamoto H. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia 1998;41:1435–41.

16.

16. Deng Y , Chen X , Ye Y. Effects of glycated protein on the expression of plasminogen activator inhibitor-1 of cultured human mesangial cells. Zhonghua Yi Xue Za Zhi 1997;77:672–5.

17.

17. Maruyama I. [Coagulation/fibrinolytic system and platelet in acute coronary syndrome]. Nippon Rinsho 1998;56:2488–92.

18.

18. Thornalley PJ. Advanced glycation and the development of diabetic complications. Unifying the involvement of glucose, methylglyoxal and oxidative stress. Endocrinol Metab 1996;3:149–66.

19.

19. Thornalley PJ. Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem Biol Interact 1998;111–112:137–51.

20.

20. McLellan AC , Thornalley PJ , Benn J , Sonksen PH. Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci (Lond) 1994;87:21–9.

21.

21. Ratliff DM , Vander Jagt DJ , Eaton RP , Vander Jagt DL. Increased levels of methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin-dependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I, and glyoxalase II-a clinical research center study. J Clin Endocrinol Metab 1996;81:488–92.

22.

22. Shinohara M , Thornalley PJ , Giardino I et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest 1998;101:1142–7.

23.

23. Miyata T , van Ypersele de Strihou C , Imasawa T et al. Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient. Kidney Int 2001;60:2351–9.

24.

24. Inagi R , Miyata T , Ueda Y et al. Efficient in vitro lowering of carbonyl stress by the glyoxalase system in conventional glucose peritoneal dialysis fluid. Kidney Int 2002;62:679–87.

25.

25. Altshuler D , Kruglyak L , Lander E. Genetic polymorphisms and disease. N Engl J Med 1998;338:1626.

26.

26. Lander ES , Schork NJ. Genetic dissection of complex traits. Science 1994;265:2037–48.

27.

27. Freeman MS , Mansfield MW , Barrett JH , Grant PJ. Genetic contribution to circulating levels of hemostatic factors in healthy families with effects of known genetic polymorphisms on heritability. Arterioscler Thromb Vasc Biol 2002;22:506–10.

28.

28. Almasy L , Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet 1998;62:1198–211.

29.

29. Thornalley PJ. The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochemistry J 1990;269:1–11.

30.

30. Kompf J , Bissbort S , Gussmann S , Ritter H. Polymorphism of red cell glyoxalase I (EI: 4.4.1.5); a new genetic marker in man. Investigation of 169 mother-child combinations. Humangenetik 1975;27(2):141–3.

31.

31. McCance DR , Dyer DG , Dunn JA et al. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 1993;91:2470–8.

32.

32. Schmidt AM , Yan SD , Wautier JL , Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84:489–97.

33.

33. Chappey O , Dosquet C , Wautier MP , Wautier JL. Advanced glycation end products, oxidant stress and vascular lesions. Eur J Clin Invest 1997;27:97–108.

34.

34. McCann VJ , Davis RE , Welborn TA , Constable IJ , Beale DG. Glyoxalase phenotypes in patients with diabetes mellitus. Austral N Z J Med 1981;11:380–2.

35.

35. Cambon-de Mouzon A , Ohayon E , Hauptmann G et al. HLA-A, B, C, DR antigens, Bf, C4 and glyoxalase I (GLO) polymorphisms in French Basques with insulin-dependent diabetes mellitus (IDDM). Tissue Antigens 1982;19:366–79.

36.

36. Kirk RL , Ranford PR , Serjeantson SW et al. HLA, complement C2, C4, properdin factor B and glyoxalase types in South Indian diabetics. Diabetes Res Clin Pract 1985;1:41–7.

37.

37. Tokunaga K , Omoto K , Juji T , Itoh T. Polymorphism of BF, C2, and GLO in Japanese patients with insulin-dependent diabetes mellitus: confirmation of an increase of BF*FT. Hum Genet 1982;62:86–8.

38.

38. Allannic H , Fauchet R , Gueguen M , Pheng SH , Dinh KT , Genetet B. Factor B (Bf) and glyoxalase genes in insulin-dependent diabetes mellitus. Diabetes Metab 1985;11:22–6.

39.

39. Kirk RL , Theophilus J , Whitehouse S , Court J , Zimmet P. Genetic susceptibility to diabetes mellitus: the distribution of properdin factor B (Bf) and glyoxalase (GLO) phenotypes. Diabetes 1979;28:949–51.

40.

40. Thornalley PJ. Population genetics of human glyoxalases. Heredity 1991;67(pt 2):139–42.

41.

41. Ranganathan S , Ciaccio PJ , Walsh ES , Tew KD. Genomic sequence of human glyoxalase-I: analysis of promoter activity and its regulation. Gene 1999;240:149–55.

42.

42. Kozak M. An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 1987;15:8125–48.

43.

43. Kageyama R , Pastan I. Molecular cloning and characterization of a human DNA binding factor that represses transcription. Cell 1989;9(5):815–25.

44.

44. Rittner C , Weber W Evidence for a ‘silent allele’ GLO0 at the glyoxalase I locus. Hum Genet 1978;42:315–18.

45.

45. Rubinstein P , Suciu-Foca N. Glyoxalase 1: a possible ‘null’ allele. Hum Hered 1979;29:217–20.

46.

46. Sparkes RS , Sparkes MC , Crist M , Anderson CE. Glyoxalase I “null” allele in a new family: identification by abnormal segregation pattern and quantitative assay. Hum Genet 1983;64:146–7.

47.

47. Ranzani G , Antonini G , Santachiara-Benerecetti AS. Red cell glyoxalase I polymorphism in Italians. Report of a variant phenotype. Hum Hered 1979;29:261–4.

48.

48. Kavathas P , DeMars R. A new variant glyoxalase I allele that is readily detectable in stimulated lymphocytes and lymphoblastoid cell lines but not in circulating lymphocytes or erythrocytes. Am J Hum Genet 1981;33:935–45.

49.

49. Beretta M , Schiliro G , Russo A et al. A new rare variant of the glyoxalase I system of the red cell: GLO- Sicily. Am J Hum Genet 1983;35:1042–7.